New drug aims to slow rare heart disease by targeting toxic proteins

NCT ID NCT06194825

First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 26 times

Summary

This study tests an investigational drug called eplontersen in 64 Chinese adults with transthyretin amyloid cardiomyopathy, a condition where abnormal proteins build up in the heart. The goal is to see if eplontersen can safely lower those protein levels compared to a placebo over 24 weeks, followed by an 80-week open-label phase. Participants must be 20-90 years old and not pregnant.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRANSTHYRETIN AMYLOID CARDIOMYOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Research Site

    Beijing, 100029, China

  • Research Site

    Beijing, 100034, China

  • Research Site

    Beijing, 100037, China

  • Research Site

    Beijing, 100191, China

  • Research Site

    Beijing, 100730, China

  • Research Site

    Changsha, 410008, China

  • Research Site

    Changsha, 410013, China

  • Research Site

    Changsha, 430033, China

  • Research Site

    Chengdu, 610041, China

  • Research Site

    Chengdu, 610072, China

  • Research Site

    Chongqing, 400010, China

  • Research Site

    Chongqing, 400042, China

  • Research Site

    Guangzhou, 510062, China

  • Research Site

    Guangzhou, 510100, China

  • Research Site

    Hangzhou, 310003, China

  • Research Site

    Hangzhou, 310014, China

  • Research Site

    Hangzhou, 310052, China

  • Research Site

    Ha’erbin, 150001, China

  • Research Site

    Jinan, 250001, China

  • Research Site

    Nanchang, 330006, China

  • Research Site

    Shanghai, 200032, China

  • Research Site

    Suzhou, 215006, China

  • Research Site

    Taiyuan, 030001, China

  • Research Site

    Wuhan, 430030, China

  • Research Site

    Wuhan, 430060, China

  • Research Site

    Xi'an, 710061, China

Conditions

Explore the condition pages connected to this study.